NCT05419362 2025-12-16
GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer
Genome & Company
Phase 2 Completed
Clinical Trials
14 trialsNCT04258956 2025-09-11
AXAGIST
Maria Sklodowska-Curie National Research Institute of Oncology
Phase 2 Completed
NCT03186326 2025-06-29
SAMCO
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT03357757 2025-06-26
LATENT
AHS Cancer Control Alberta
Phase 2 Completed
NCT04513951 2025-01-09
AVETRIC
Gruppo Oncologico del Nord-Ovest
Phase 2 Completed
NCT03783936 2023-12-19
Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas
Hoosier Cancer Research Network
Phase 2 Completed
NCT03854799 2023-10-19
AVANA
Gruppo Oncologico del Nord-Ovest
Phase 2 Completed
NCT03299660 2023-03-16
Avelumab With Chemoradiation in Locally Advanced Rectal Cancer
Peter MacCallum Cancer Centre, Australia
Phase 2 Completed
NCT03174405 2022-09-29
AVETUX
AIO-Studien-gGmbH
Phase 2 Completed
NCT04561336 2022-05-05
Avelumab Plus Cetuximab in Pre-treated RAS Wild Type Metastatic Colorectal Cancer
University of Campania Luigi Vanvitelli
Phase 2 Completed
NCT03389126 2021-03-17
AvelumabHCC
Seoul National University Hospital
Phase 2 Completed
NCT02625623 2020-11-24
Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)
EMD Serono
Phase 3 Completed
NCT03152565 2020-10-06
AVEVAC
Grupo Espanol Multidisciplinario del Cancer Digestivo
Phase 1/2 Completed
NCT03258398 2019-07-18
A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer
Effector Therapeutics
Phase 2 Completed